(Reuters) – Johnson & Johnson said its experimental sirukumab treatment for rheumatoid arthritis showed mixed results against AbbVie Inc's top-selling Humira in a large trial. By one measure, patients with moderate to severe disease who took sirukumab showed significantly greater improvement in the Phase III study than those taking Humira, J&J said on Saturday. In the 559-patient study, those taking sirukumab scored declines after 24 weeks of 2.58 with a low dose and 2.96 with a high dose on a widely used nine-point scale of disease activity.
See the rest here:
J&J arthritis drug goes up against Humira, with mixed results
